Transgenic Lung Model for Pulmonary Tumor Research
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal models are inadequate for studying the molecular mechanisms of pulmonary adenocarcinoma, particularly in terms of tissue-specific expression of VEGF-A165, which is crucial for understanding tumorigenesis and developing therapeutic strategies for lung cancer.
Innovation Solution
A transgenic non-human animal model is created through genetic engineering to express VEGF-A165 specifically in lung cells, using a CCSP promoter to ensure targeted expression, allowing for the investigation of pulmonary adenocarcinoma mechanisms and therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a transgenic animal model is created to express VEGF-A165 specifically in lung cells, then the ability to study pulmonary adenocarcinoma mechanisms is improved, but the complexity of the manufacturing process increases
Solution Approach 1:
The expression vector is divided into distinct functional segments: the CCSP promoter region for lung-specific expression control, the VEGF-A165 coding sequence for the target protein, and regulatory elements for proper gene expression. This segmentation allows independent optimization and verification of each component, reducing overall system complexity while ensuring reliable tissue-specific expression.
Solution Approach 2:
The CCSP promoter is used to provide local quality control by restricting VEGF-A165 expression specifically to lung cells ( Clara cells and type II alveolar epithelial cells). This localized expression strategy ensures that the transgenic model accurately mimics the specific molecular mechanisms of pulmonary adenocarcinoma without causing systemic effects, thereby improving model reliability while using a targeted rather than ubiquitous expression approach.
2Measurement precision
If tissue-specific expression of VEGF-A165 is achieved in lung cells, then the accuracy of tumorigenesis research is improved, but the difficulty of constructing the expression vector increases
Solution Approach 1:
The CCSP (clara cell secretory protein) promoter serves as an intermediary element that mediates between the research goal (studying pulmonary adenocarcinoma) and the molecular mechanism (VEGF-A165 expression). This well-characterized lung-specific promoter acts as a reliable mediator to drive tissue-specific expression, allowing precise tumorigenesis research while using a proven, readily available regulatory element rather than requiring de novo promoter discovery and characterization.
3Adaptability or versatility
If VEGF-A165 is expressed specifically in lung bronchus epidermal cells, then the ability to investigate pulmonary adenocarcinoma therapeutic effects is improved, but the time required for model development increases
Solution Approach 1:
The expression vector is constructed in advance with all necessary components (CCSP promoter, VEGF-A165 coding sequence, regulatory elements) properly assembled and verified for functionality. This preliminary construction and validation of the complete expression system allows for rapid generation of transgenic animals once the vector is ready, reducing the overall development time while ensuring the model's versatility for therapeutic effect investigation from the outset.
Data Source
AI summary
The present invention is a method for manufacturing an animal model for researching a pulmonary tumor and a use thereof. A transgenic non-human animal of the present invention is prepared by embryonic gene microinjection and possesses a tissue-specific expression of vascular endothelial growth factor A165 (VEGF-A165) in lung. Through the expression of vascular endothelial growth factor A165, the lung cells in the transgenic non-human animal of the present invention have inflammatory, vascularogenesis and angiogenesis responses or induce lung tumors. Thus, the non-human animal of the present invention can serve as an animal model for analyzing the regulation and the anti-tumor drugs screening of pulmonary adenocarcinoma.